Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silymarin for prevention of vancomycin-induced nephrotoxicity
IRCT20161010030246N6Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of silymarin in nephrotoxicity (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Incidence of vancomycin-induced nephrotoxicity. Started Jun 2023; status: completed.
02
Drugs
silymarin
03
Conditions
nephrotoxicity
Beyond the preview
Go deeper on IRCT20161010030246N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20161010030246N6.